Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EGFR Inhibitor HM61713

Known as: HM61713 
An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non-small cell lung cancer. Tyrosine kinase… Expand
Is this relevant?
Review
2017
Review
2017
EGFR T790M mutation leads to resistance to most of clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
9055Background: T790M mediates acquired resistance to 1st/2nd generation EGFR-TKIs. BI 1482694 is a 3rd generation TKI active… Expand
Is this relevant?
2016
2016
s, ELCC 2016 Journal of Thoracic Oncology Vol. 11, Suppl. 4S (2016) S113–S142 
Is this relevant?
Review
2016
Review
2016
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs… Expand
  • table 2
  • table 3
  • table 3
  • figure 1
  • table 4
Is this relevant?
2016
2016
effusion. There were 410 male and 120 female, with a mean age of 54 years. In 401 patients VATS was performed under general… Expand
Is this relevant?
2015
2015
8084 Background: HM61713 is an orally available EGFR mutation-specific inhibitor with sparing EGFR WT tumors that previously… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
8011 Background: HM61713 is a novel, oral, selective inhibitor for EGFR mutations including both activating mutations and T790M… Expand
Is this relevant?
2014
2014
Introduction: Activating mutations of EGFR are well known as oncogenic driver mutations in lung adenocarcinoma. Currently, EGFR… Expand
Is this relevant?